Key facts
- Nucleus (Healthcare Technology Systems)’s last known valuation is $53.5M (Jan 2022).
- It has raised $31.5M; the latest was Later Stage VC ($14.0M) in Jan 2025.
- Notable investors include Founders Fund, Samsung NEXT Ventures, Pareto Holdings, Quiet Capital, Balaji Srinivasan — 43 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 43 names
- ·Watchlist + deal alerts for Nucleus (Healthcare Technology Systems)
- ·The full record, as it builds
Funding rounds
No funding rounds for Nucleus (Healthcare Technology Systems) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nucleus (Healthcare Technology Systems)
Operator of a biotechnology research platform intended to offer next-generation consumer genetic testing and analysis. The company's platform integrates comprehensive genomic sequencing, detailed health reports, and actionable insights based on a deeper DNA analysis compared to industry standards, enabling individuals to understand their genetic predispositions better, monitor health risks, and make informed lifestyle and medical decisions for long-term health management.
- Sector
- Healthcare
- HQ
- Bloomington, MN, United States
- Founded
- 2021
- Employees
- 41
- Website
- mynucleus.com/
- Ownership
- Privately Held (backing)
Nucleus (Healthcare Technology Systems) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nucleus (Healthcare Technology Systems) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nucleus (Healthcare Technology Systems) in its N-PORT filings yet. We sweep new filings monthly.